Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,369 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,405)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06114511 | A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 78 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06176989 | Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors | recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 |
| NCT06258811 | Neoadjuvant Immunochemotherapy for LAOSCC | recruiting | Phase 3 | 134 | Lai-ping ZhongOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06271291 | Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts | recruiting | — | 30,000 | Mayo ClinicOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06329869 | Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma(SG-ESCC) | recruiting | Phase 2 | 35 | National Taiwan University HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06375915 | Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy(PM-CARE) | recruiting | Phase 2 | 33 | Francesco De CobelliOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06439836 | Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy | recruiting | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06529822 | Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease | recruiting | Phase 1 | 64 | Washington University School of MedicineOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06732401 | Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 630 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06736379 | Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer | recruiting | Phase 1 | 41 | VLP TherapeuticsINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06745882 | Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC | recruiting | Phase 2 | 318 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06773910 | BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)(TIGOS-LS) | active not recruiting | Phase 2 | 250 | SCRI Development Innovations, LLCOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06781567 | Clinical Trial of HG146 Administered to Participants With Adenoid Cystic Carcinoma(HG146) | recruiting | Phase 2 | 140 | HitGen Inc.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06811038 | iCanQuit Smoking Cessation Among Hispanic Adults | not yet recruiting | Phase 3 | 854 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06929845 | Organoid Models of Hepatocellular Carcinoma | recruiting | N/A | 150 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06980077 | Ivonescimab for the Treatment of Thymic Cancer | recruiting | Phase 2 | 25 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07162480 | Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I) | recruiting | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07176000 | Tailored Patient Navigation to Improve the Uptake of Lung Cancer Screening in Tribal Communities in Western Washington State, SACRED LUNGS Trial | recruiting | N/A | 237 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07200141 | Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer(SIB-NCRT) | recruiting | Phase 2 | 156 | Peking Union Medical College HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07431827 | MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)(KANDLELIT-013) | recruiting | Phase 3 | 400 | Merck Sharp & Dohme LLCINDUSTRY | 18 | Sep 21, 2026 | clinicaltrials |
| NCT07495124 | IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence | recruiting | Phase 2 | 26 | University of WashingtonOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07629960 | A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations | recruiting | Phase 1 / Phase 2 | 265 | Blueprint Medicines CorporationINDUSTRY | 2 | Sep 21, 2026 | clinicaltrials |
| NCT07639138 | Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC | recruiting | Phase 2 | 32 | Shunda DuOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07645651 | Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer | recruiting | Phase 1 | 15 | University of WashingtonOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07793695 | Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma(ZINC-1LT/IOHCC) | recruiting | Phase 2 | 60 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07804056 | A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer | recruiting | Phase 3 | 194 | Hamlet Pharma ABINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07823725 | TailorDose Lung: Decentralized TDM of Taxanes and ALK Inhibitors Using Capillary Self-Sampling(TD-Lung) | not yet recruiting | N/A | 40 | Karolinska InstitutetOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07829926 | Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer(LENTIG-HCC) | not yet recruiting | Phase 2 | 120 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT07830355 | Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph Nodes | not yet recruiting | Phase 2 | 75 | Shanghai Chest HospitalOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT07831330 | Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer | not yet recruiting | Phase 2 | 59 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT07831863 | A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy | not yet recruiting | Phase 3 | 600 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07832006 | Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 30 | Shunda DuOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07832227 | Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial(SIERRA) | not yet recruiting | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT01334021 | Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer | active not recruiting | Phase 2 | 1,100 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT02874885 | Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer | active not recruiting | — | 341 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03391869 | Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 339 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03410043 | Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study | active not recruiting | Phase 2 | 173 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03776487 | Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer | active not recruiting | Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04090398 | Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04291755 | Development and Analysis of a Stool Bank for Cancer Patients | enrolling by invitation | — | 100 | Persephone BiosciencesINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04871139 | An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer | active not recruiting | N/A | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04985565 | Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer | active not recruiting | N/A | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05027633 | Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA) | recruiting | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05048212 | A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases | recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05267626 | Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | recruiting | Phase 1 / Phase 2 | 159 | Aulos Bioscience, Inc.INDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT05327686 | Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial(SAMURAI) | recruiting | Phase 2 | 240 | NRG OncologyOTHER | 4 | Sep 18, 2026 | clinicaltrials |
| NCT05863052 | Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population | active not recruiting | — | 72 | University of OklahomaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06077760 | A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)(INTerpath-002) | active not recruiting | Phase 3 | 868 | Merck Sharp & Dohme LLCINDUSTRY | 33 | Sep 18, 2026 | clinicaltrials |
| NCT06161545 | Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06398418 | R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors | recruiting | Phase 1 | 33 | Rise Therapeutics LLCINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 21, 2026source: clinicaltrials